On July 8th, Gelunhui reported that CSPC Innovation Pharmaceutical's majority-owned subsidiary, CSPC Pharma, recently received notification from the US Food and Drug Administration (FDA) that the clinical trial application for injection drug SYS6023 filed by CSPC Pharma has been approved by the FDA and can be carried out in the United States.
SYS6023 is a monoclonal antibody drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, release toxins, and kill tumor cells. The drug has been approved for clinical use in the treatment of advanced solid tumors. Preclinical studies have shown that SYS6023 has good anti-tumor effects on various types of cancer and has high clinical development value. The product has submitted multiple patent applications.